Profile
Mr. Neil S.
Belloff was previously employed as a Secretary & General Counsel by Acorda Therapeutics, Inc., a COO, Secretary, EVP & General Counsel by Eloxx Pharmaceuticals, Inc., a Senior Corporate Counsel by Celgene Corp., and an Executive VP, US Corporate & Securities Counsel by Deutsche Telekom AG.
He received his undergraduate degree from Queens College, a graduate degree from New York University and a graduate degree from Quinnipiac University School of Law.
Former positions of Neil Belloff
| Companies | Position | End |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | General Counsel | 21/08/2024 |
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 25/08/2021 |
| CELGENE | Corporate Officer/Principal | - |
| DEUTSCHE TELEKOM AG | Corporate Officer/Principal | - |
Training of Neil Belloff
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Deutsche Telekom AG
Deutsche Telekom AG Major TelecommunicationsCommunications Provides telecommunication services | Communications |
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Queens College
Queens College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quinnipiac University School of Law
Quinnipiac University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that discovers and develops therapeutics to treat cystic fibrosis, inherited retinal disorders and other diseases | Health Technology |
- Stock Market
- Insiders
- Neil Belloff
















